Methandrostenolone

Methandrostenolone

Error creating thumbnail: File missing
Clinical data
Pregnancy category	US: X (Contraindicated)
Routes of administration	Oral
ATC code	A14AA03 (WHO)
Legal status
Legal status	DEA Schedule III (US)
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	4.5-6 hours
Excretion	Renal
Identifiers
IUPAC name (8S,9S,10S,13S,14S,17S)-17-hydroxy-10, 13,17-trimethyl-7,8,9,11,12,14,15,16- octahydro-6H-cyclopenta[a]phenanthren-3-one
CAS Number	72-63-9
PubChem CID	6300
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H28O2
Molar mass	300.441 g/mol

WikiDoc Resources for Methandrostenolone
Articles
Most recent articles on Methandrostenolone Most cited articles on Methandrostenolone Review articles on Methandrostenolone Articles on Methandrostenolone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Methandrostenolone Images of Methandrostenolone Photos of Methandrostenolone Podcasts & MP3s on Methandrostenolone Videos on Methandrostenolone
Evidence Based Medicine
Cochrane Collaboration on Methandrostenolone Bandolier on Methandrostenolone TRIP on Methandrostenolone
Clinical Trials
Ongoing Trials on Methandrostenolone at Clinical Trials.gov Trial results on Methandrostenolone Clinical Trials on Methandrostenolone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Methandrostenolone NICE Guidance on Methandrostenolone NHS PRODIGY Guidance FDA on Methandrostenolone CDC on Methandrostenolone
Books
Books on Methandrostenolone
News
Methandrostenolone in the news Be alerted to news on Methandrostenolone News trends on Methandrostenolone
Commentary
Blogs on Methandrostenolone
Definitions
Definitions of Methandrostenolone
Patient Resources / Community
Patient resources on Methandrostenolone Discussion groups on Methandrostenolone Patient Handouts on Methandrostenolone Directions to Hospitals Treating Methandrostenolone Risk calculators and risk factors for Methandrostenolone
Healthcare Provider Resources
Symptoms of Methandrostenolone Causes & Risk Factors for Methandrostenolone Diagnostic studies for Methandrostenolone Treatment of Methandrostenolone
Continuing Medical Education (CME)
CME Programs on Methandrostenolone
International
Methandrostenolone en Espanol Methandrostenolone en Francais
Business
Methandrostenolone in the Marketplace Patents on Methandrostenolone
Experimental / Informatics
List of terms related to Methandrostenolone

Methandrostenolone (Dianabol) is an anabolic steroid originally developed by John Ziegler and released in the US in 1958 by Ciba. It was used as an aid to muscle growth by bodybuilders until its ban by the FDA under the Controlled Substances Act.

Methandrostenolone does not react strongly with the androgen receptor, instead relying on activity not mediated by the receptor for its effects. These include dramatic increases in protein synthesis, glycogenolysis, and muscle strength over a short space of time. However, due to its mode of action, it decreases the rate of cell respiration and decreases production of red blood cells. In high doses (30 mg or more per day), side effects such as gynaecomastia, high blood pressure, acne and male pattern baldness may begin to occur. The drug causes severe masculinising effects in women even at low doses. In addition, it is metabolized into estradiol by aromatase. This means that without the administration of aromatase inhibitors such as Anastrozole or Aminoglutethimide, estrogenic effects will appear over time in men. Many users will combat the estrogenic side effects with Nolvadex or Clomid. In addition, as with other 17α-alkylated steroids, the use of methandrostenolone over extended periods of time can result in liver damage without appropriate care.

In the early 1960s, doctors commonly prescribed a tablet per day for women as a tonic. This use was quickly discontinued upon discovery of the heavily masculinising effects of methandrostenolone. However, despite the lack of any known therapeutic applications, the drug remained legal until the early 1990s.

The 17α-methylation of the steroid does allow it to pass through the liver without being broken down (hence causing the aforementioned damage to the liver) allowing it to be taken orally. It also has the effect of decreasing the steroid's affinity for sex hormone binding globulin, a protein that de-activates steroid molecules and prevents them from further reactions with the body. As a result, methandrostenolone is significantly more active than an equivalent quantity of testosterone, resulting in rapid growth of muscle tissue. However, the concomitant elevation in estrogen levels - a result of the aromatization of methandrostenolone - results in significant water retention. This gives the appearance of great gains in mass and strength, which prove to be temporary once the steroid is discontinued and water weight drops. Because of this, it is often used by bodybuilders only at the start of a "steroid cycle", to facilitate rapid strength increases and the appearance of great size, while compounds such as testosterone or nandrolone with long acting esters build up in the body to an appreciable amount capable of supporting anabolic function on their own.

References

• Death due to Liver Failure Following the Use of Methandrostenolone Edmund M. Wilder, Can Med Assoc J. 1962 October 6; 87(14): 768–769.
• Some Experiences with a New Anabolic Steroid (Methandrostenolone) George L. Foss, Br Med J. 1960 April 30; 1(5182): 1300–1305.
• The Effect of Methandrostenolone on Nitrogen Excretion Following Open-Heart Surgery Walter Zingg, Can Med Assoc J, Oct.9, 1965, vol 93

Template:WikiDoc Sources